フォロー
Shoya Iwanami
Shoya Iwanami
その他の名前岩波翔也, S. Iwanami
Division of Natural Science, Graduate School of Science, Nagoya University, Japan
確認したメール アドレス: f.mail.nagoya-u.ac.jp - ホームページ
タイトル
引用先
引用先
Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment
H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ...
Iscience 24 (4), 2021
188*2021
A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2
KS Kim, K Ejima, S Iwanami, Y Fujita, H Ohashi, Y Koizumi, Y Asai, ...
PLoS biology 19 (3), e3001128, 2021
146*2021
Factors associated with COVID-19 vaccine booster hesitancy: A retrospective cohort study, Fukushima vaccination community survey
M Yoshida, Y Kobashi, T Kawamura, Y Shimazu, Y Nishikawa, F Omata, ...
Vaccines 10 (4), 515, 2022
642022
Estimation of the incubation period of COVID-19 using viral load data
K Ejima, KS Kim, C Ludema, AI Bento, S Iwanami, Y Fujita, H Ohashi, ...
Epidemics 35, 100454, 2021
602021
Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study
S Iwanami, K Ejima, KS Kim, K Noshita, Y Fujita, T Miyazaki, S Kohno, ...
PLoS medicine 18 (7), e1003660, 2021
50*2021
Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro
K Shionoya, M Yamasaki, S Iwanami, Y Ito, S Fukushi, H Ohashi, W Saso, ...
Frontiers in Microbiology 12, 651403, 2021
282021
Revisiting the guidelines for ending isolation for COVID-19 patients
YD Jeong, K Ejima, KS Kim, S Iwanami, AI Bento, Y Fujita, IH Jung, ...
Elife 10, e69340, 2021
252021
Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study
K Ejima, KS Kim, AI Bento, S Iwanami, Y Fujita, K Aihara, K Shibuya, ...
BMC Infectious Diseases 22 (1), 656, 2022
24*2022
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA. 1 and BA. 2
H Ohashi, T Hishiki, D Akazawa, KS Kim, J Woo, K Shionoya, ...
Antiviral Research 205, 105372, 2022
212022
Designing isolation guidelines for COVID-19 patients with rapid antigen tests
YD Jeong, K Ejima, KS Kim, W Joohyeon, S Iwanami, Y Fujita, IH Jung, ...
Nature Communications 13 (1), 4910, 2022
192022
A highly pathogenic simian/human immunodeficiency virus effectively produces infectious virions compared with a less pathogenic virus in cell culture
S Iwanami, Y Kakizoe, S Morita, T Miura, S Nakaoka, S Iwami
Theoretical Biology and Medical Modelling 14, 1-13, 2017
192017
Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection
KS Kim, S Iwanami, T Oda, Y Fujita, K Kuba, T Miyazaki, K Ejima, S Iwami
Life Science Alliance 4 (10), 2021
162021
Potential anti-mpox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments
D Akazawa, H Ohashi, T Hishiki, T Morita, S Iwanami, KS Kim, YD Jeong, ...
The Journal of infectious diseases 228 (5), 591-603, 2023
13*2023
Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma
S Iwanami, K Kitagawa, H Ohashi, Y Asai, K Shionoya, W Saso, ...
PLoS biology 18 (7), e3000562, 2020
102020
Quantitative Immunology by Data Analysis Using Mathematical Models
S Iwanami, S Iwami
Encyclopedia of Bioinformatics and Computational Biology 2, 984-992, 2019
92019
Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model
K Ejima, KS Kim, S Iwanami, Y Fujita, M Li, RS Zoh, K Aihara, T Miyazaki, ...
Journal of the Royal Society Interface 18 (177), 20200947, 2021
82021
Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience 24: 102367
H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ...
82021
Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir
S Torii, KS Kim, J Koseki, R Suzuki, S Iwanami, Y Fujita, YD Jeong, J Ito, ...
PLoS Pathogens 19 (3), e1011231, 2023
72023
Multidrug treatment with nelfinavir and cepharanthine against COVID-19. bioRxiv. 2020 Apr 15
H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa
View Article, 0
6
Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience, 24 (4), 102367
H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ...
52021
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20